| Popis: |
Susmita Aryal,1 Sanghyo Park,1 Hyungkyu Park,1 Chaewon Park,1 Woo Cheol Kim,1 Deepika Thakur,1 Young-Joo Won,2 Jaehong Key1 1Department of Biomedical Engineering, Yonsei University, Wonju, Gangwon Province, 26493, Korea; 2Division of Health Administration, College of Software Digital Healthcare Convergence, Yonsei University, Wonju, Gangwon State, 26493, KoreaCorrespondence: Jaehong Key, Department of Biomedical Engineering, Yonsei University, 1 Yonseidae-Gil, Wonju, Gangwon State, 26493, Korea, Tel +82-33-760-2857, Fax +82-33-760-2919, Email jkey@yonsei.ac.krAbstract: Lung cancer is one of the most common malignant tumors worldwide and is characterized by high morbidity and mortality rates and a poor prognosis. It is the leading cause of cancer-related death in the United States and worldwide. Most patients with lung cancer are treated with chemotherapy, radiotherapy, or surgery; however, effective treatment options remain limited. In this review, we aim to provide an overview of clinical trials, ranging from Phase I to III, conducted on drug delivery systems for lung cancer treatment. The trials included oral, inhaled, and intravenous administration of therapeutics. Furthermore, the study also talks about the evolving paradigm of targeted therapy and immunotherapy providing promising directions for personalized treatment. In addition, we summarize the best results and limitations of these drug delivery systems and discuss the potential capacity of nanomedicine.Keywords: lung cancer, clinical trials, nanomedicine, oral, intravenous, inhalation |
